CN119053613A - 化合物的多晶型和制备化合物的多晶型的方法 - Google Patents
化合物的多晶型和制备化合物的多晶型的方法 Download PDFInfo
- Publication number
- CN119053613A CN119053613A CN202380034735.3A CN202380034735A CN119053613A CN 119053613 A CN119053613 A CN 119053613A CN 202380034735 A CN202380034735 A CN 202380034735A CN 119053613 A CN119053613 A CN 119053613A
- Authority
- CN
- China
- Prior art keywords
- crystalline form
- compound
- degrees
- fibrosis
- ray powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
- C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
- C07C215/08—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with only one hydroxy group and one amino group bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263311869P | 2022-02-18 | 2022-02-18 | |
| US63/311,869 | 2022-02-18 | ||
| PCT/US2023/012898 WO2023158607A1 (en) | 2022-02-18 | 2023-02-13 | Polymorphic forms and methods of producing polymorphic forms of a compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN119053613A true CN119053613A (zh) | 2024-11-29 |
Family
ID=87578977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202380034735.3A Pending CN119053613A (zh) | 2022-02-18 | 2023-02-13 | 化合物的多晶型和制备化合物的多晶型的方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250034183A1 (https=) |
| EP (1) | EP4479409A4 (https=) |
| JP (1) | JP2025508746A (https=) |
| KR (1) | KR20240152889A (https=) |
| CN (1) | CN119053613A (https=) |
| AU (1) | AU2023221889A1 (https=) |
| CA (1) | CA3252569A1 (https=) |
| MX (1) | MX2024010008A (https=) |
| WO (1) | WO2023158607A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES3053674T3 (en) | 2018-03-22 | 2026-01-23 | Viking Therapeutics Inc | Crystalline forms and methods of producing crystalline forms of a compound |
| WO2020117962A1 (en) | 2018-12-05 | 2020-06-11 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis and inflammation |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1882327A (zh) * | 2003-11-19 | 2006-12-20 | 症变治疗公司 | 含磷的新的拟甲状腺素药 |
| EP1891080A2 (en) * | 2005-05-26 | 2008-02-27 | Metabasis Therapeutics, Inc. | Novel phosphorus-containing thyromimetics |
| WO2006128056A2 (en) * | 2005-05-26 | 2006-11-30 | Metabasis Therapeutics, Inc. | Novel phosphinic acid-containing thyromimetics |
| WO2020117962A1 (en) * | 2018-12-05 | 2020-06-11 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis and inflammation |
-
2023
- 2023-02-13 JP JP2024548633A patent/JP2025508746A/ja active Pending
- 2023-02-13 EP EP23756786.2A patent/EP4479409A4/en active Pending
- 2023-02-13 KR KR1020247031018A patent/KR20240152889A/ko active Pending
- 2023-02-13 MX MX2024010008A patent/MX2024010008A/es unknown
- 2023-02-13 CN CN202380034735.3A patent/CN119053613A/zh active Pending
- 2023-02-13 WO PCT/US2023/012898 patent/WO2023158607A1/en not_active Ceased
- 2023-02-13 US US18/836,713 patent/US20250034183A1/en active Pending
- 2023-02-13 AU AU2023221889A patent/AU2023221889A1/en active Pending
- 2023-02-13 CA CA3252569A patent/CA3252569A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025508746A (ja) | 2025-04-10 |
| EP4479409A1 (en) | 2024-12-25 |
| AU2023221889A1 (en) | 2024-08-15 |
| EP4479409A4 (en) | 2025-10-22 |
| US20250034183A1 (en) | 2025-01-30 |
| CA3252569A1 (en) | 2023-08-24 |
| KR20240152889A (ko) | 2024-10-22 |
| MX2024010008A (es) | 2024-08-22 |
| WO2023158607A1 (en) | 2023-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11292772B2 (en) | Salts of an epidermal growth factor receptor kinase inhibitor | |
| CN104302178B (zh) | 表皮生长因子受体激酶抑制剂的固体形式 | |
| EP3846809B1 (en) | 2,6-diamino pyridine compounds | |
| US10301287B2 (en) | Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate | |
| US10150770B2 (en) | Crystal form of bisulfate of JAK inhibitor and preparation method therefor | |
| CN119053613A (zh) | 化合物的多晶型和制备化合物的多晶型的方法 | |
| CN111518101B (zh) | 吡咯并嘧啶衍生物及其用途 | |
| WO2019001383A1 (zh) | 用于抑制Bcl-2蛋白的N-苯磺酰基苯甲酰胺类化合物及其组合物及应用 | |
| JP2025148406A (ja) | アクチビン受容体様キナーゼ阻害剤の塩及び結晶形態 | |
| TWI826013B (zh) | 咪唑啉酮衍生物的晶型 | |
| US20230026869A1 (en) | Crystal form of nucleoprotein inhibitor and use thereof | |
| US20240262785A1 (en) | Solid Forms, Salts and Polymorphs of Anti-fibrotic Compounds | |
| EP4549435A1 (en) | Pharmaceutically acceptable salt and crystal form of nitrogen-containing bridge heterocyclic derivative, and method for preparing same | |
| WO2022262841A1 (zh) | 一种螺环化合物的盐型、晶型及其制备方法 | |
| JP7536036B2 (ja) | Ａ２ａ受容体アンタゴニストの塩形態、結晶形態及びその製造方法 | |
| US12030840B2 (en) | Elafibranor salts | |
| AU2020274362B2 (en) | Substituted fluorine-containing imidazole salt compound, preparation method therefor, pharmaceutical composition thereof and use thereof | |
| US10399946B2 (en) | Solid forms of an S-Nitrosoglutathione reductase inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |